InvestorsHub Logo
Followers 5
Posts 488
Boards Moderated 0
Alias Born 05/01/2019

Re: SPORTYNORTY post# 5925

Saturday, 11/14/2020 3:42:35 PM

Saturday, November 14, 2020 3:42:35 PM

Post# of 14065
Thanks, similar to 10K April 2019 and earlier PR. Minus the “drive revenue and profits organically.”

“On October 25, 2018, the Company announced that, in connection with the FDA PMA Class III approval process for HemoStyp, UHP has been contacted by several medical technology companies that are active in the surgical equipment and hemostatic products sectors, and who had expressed an interest in the Company's products and business strategy. In response to these inbound contacts, and to maximize shareholder value, the Company's board of directors has determined to conduct a review of strategic alternatives, which include a potential sale of the Company, joint venture or other commercial partnership, or a standalone growth plan. To assist in this review, the Company has retained Société Générale to serve as financial advisor to the Company and it has retained the law firm of Ruskin Moscou Faltischek PC to assist in the strategic review. There can be no assurances that any specific transaction will occur as a result of the retention of these firms.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent UEEC News